Correlation of PSMA PET and Post-therapy SPECT Imaging Metrics with Absorbed Doses for 177Lu-PSMA-617 Therapy

被引：0
|
作者：
Meyer, Catherine [1 ]
Yilmaz, Burcak [1 ]
Winters, Celeste [1 ]
Mench, Anna [1 ]
Mallak, Nadine [1 ]
Mittra, Erik [1 ]
机构：
[1] OHSU, Portland, OR USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242420
引用
收藏
页数：3
相关论文
共 50 条
  • [41] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Thomas J. W. Klein Nulent
    Robert J. J. van Es
    Stefan M. Willems
    Arthur. J. A. T. Braat
    Lot A. Devriese
    Remco de Bree
    Bart de Keizer
    EJNMMI Research, 11
  • [42] Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?
    Fermawi, S.
    Buehner, T.
    Kalarn, S.
    Sabottke, C.
    Recio-Boiles, A.
    Savir-Baruch, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S363 - S363
  • [43] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [44] Absorbed dose prediction for subsequent therapy cycles from 1st cycle of 177Lu-PSMA-617 therapy of mCRPC patients
    Brosch-Lenz, J.
    Colpo, N.
    Bloise, I.
    Hou, X.
    Parulekar, W. R.
    Dellar, C.
    Saad, F.
    Chi, K.
    Wilson, D.
    Benard, F.
    Rahmim, A.
    Uribe, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S179 - S179
  • [45] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [46] Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Lee, Vivian
    O'Brien, Sophia
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) : 301 - 304
  • [47] Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment.
    Leonio, Maria Isabel
    Ferri, Valentina
    Duan, Heying
    Shah, Jagruti
    Moradi, Farshad
    Mari Aparici, Carina
    Franc, Benjamin Lewis
    Davidzon, Guido
    Bergstrom, Colin P.
    Fan, Alice C.
    Shah, Sumit
    Khaki, Ali Raza
    Srinivas, Sandy
    Iagaru, Andrei
    Iagaru, Andrei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 32 - 32
  • [48] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [49] 177LU-PSMA-617 PRODUCTION AND QUALITY CONTROL AT THE RAH
    Girvin, Mark
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 14 - 14
  • [50] Ga-68-PSMA-11 PET Imaging as a Predictor for Absorbed Doses in Organs at Risk and Small Lesions in Lu-177-PSMA-617 Treatment
    Peters, S.
    Hofferber, R.
    Prive, B.
    De Bakker, M.
    Gotthardt, M.
    De lange, F.
    Muselaers, C.
    Mehra, N.
    Witjes, A.
    Costa, P.
    Nagarajah, J.
    Konijnenberg, M.
    Jentzen, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S76 - S76
12345